田口 和明KAZUAKI TAGUCHI

Last Updated :2025/07/18

所属・職名
大学院医系科学研究科(薬) 教授
メールアドレス
taguakihiroshima-u.ac.jp

基本情報

主な職歴

  • 2025年04月01日, 広島大学, 大学院医系科学研究科 薬学部, 教授
  • 2021年04月01日, 2025年03月31日, 慶応義塾大学, 薬学部, 准教授
  • 2018年04月01日, 2021年03月31日, 慶応義塾大学, 薬学部, 専任講師
  • 2013年04月01日, 2018年03月31日, 崇城大学, 薬学部, 助教
  • 2011年04月01日, 2013年03月31日, 熊本大学医学部附属病院, 薬剤部, 薬剤師

学歴

  • 熊本大学大学院, 薬学教育部博士後期課程, 日本, 2008年04月, 2011年03月
  • 熊本大学大学院, 薬学教育部博士前期課程, 日本, 2006年04月, 2008年03月
  • 熊本大学, 薬学部, 日本, 2002年04月, 2006年03月

担当主専攻プログラム

  • 薬科学プログラム
  • 薬学プログラム

研究分野

  • 総合理工 / ナノ・マイクロ科学 / ナノバイオサイエンス
  • 医歯薬学 / 薬学 / 創薬化学
  • 医歯薬学 / 薬学 / 医療系薬学

所属学会

  • 日本DDS学会
  • 日本医療薬学会
  • 日本化学療法学会
  • 日本薬剤学会
  • 日本薬学会
  • 日本血液代替物学会
  • 日本薬物動態学会

教育活動

授業担当

  1. 2025年, 学部専門, セメスター(前期), 薬学研究方法論演習A
  2. 2025年, 学部専門, セメスター(後期), 薬学研究方法論演習B
  3. 2025年, 学部専門, 1ターム, 臨床医学概論I
  4. 2025年, 学部専門, 2ターム, 薬剤経済学
  5. 2025年, 学部専門, 3ターム, 臨床評価学
  6. 2025年, 学部専門, 3ターム, 日本薬局方演習
  7. 2025年, 学部専門, 3ターム, 臨床事前実習
  8. 2025年, 学部専門, 通年, 基礎研究I
  9. 2025年, 学部専門, 通年, 基礎研究II
  10. 2025年, 学部専門, セメスター(後期), 基礎研究III
  11. 2025年, 学部専門, 通年, 臨床研究I
  12. 2025年, 学部専門, 通年, 臨床研究II
  13. 2025年, 学部専門, 通年, 臨床研究III
  14. 2025年, 博士課程・博士課程後期, 4ターム, 薬物治療学
  15. 2025年, 博士課程・博士課程後期, セメスター(前期), 臨床薬物治療学特別演習
  16. 2025年, 博士課程・博士課程後期, セメスター(後期), 臨床薬物治療学特別演習
  17. 2025年, 博士課程・博士課程後期, セメスター(前期), 臨床薬物治療学特別研究
  18. 2025年, 博士課程・博士課程後期, セメスター(後期), 臨床薬物治療学特別研究
  19. 2025年, 修士課程・博士課程前期, セメスター(前期), 薬物治療学特論演習
  20. 2025年, 修士課程・博士課程前期, セメスター(後期), 薬物治療学特論演習
  21. 2025年, 修士課程・博士課程前期, セメスター(前期), 薬物治療学特別研究
  22. 2025年, 修士課程・博士課程前期, セメスター(後期), 薬物治療学特別研究

研究活動

学術論文(★は代表的な論文)

  1. Development and validation of a population pharmacokinetic model of vancomycin for patients of advanced age, Journal of Pharmaceutical Health Care and Sciences, 11巻, 1号, 20251201
  2. Shortening the interval between the first and the second dose of vancomycin facilitates rapid achievement of the target AUC without increasing the risk of acute kidney injury, provided the AUC on the second day is appropriately controlled: a multicenter retrospective study, Journal of Pharmaceutical Health Care and Sciences, 11巻, 1号, 20251201
  3. Combined dual β-lactams and diazabicyclooctane β-lactamase inhibitor is highly effective against Mycobacterium abscessus species in vitro, Journal of Global Antimicrobial Resistance, 42巻, pp. 142-150, 20250501
  4. Methemoglobin-Encapsulating Liposome: A Low-Risk Intravascular Contrast Agent for Magnetic Resonance Imaging, ACS Applied Bio Materials, 8巻, 4号, pp. 2838-2846, 20250421
  5. 医療用一般用共用医薬品(仮称)の創設提言に対する薬剤師の認知および見解に関する実態把握調査, 医療薬学, 51巻, 4号, pp. 196-202, 20250401
  6. Direct comparison of the effects of first- and second-generation H1-receptor blockers on motor functions in mice, Pharmazie, 80巻, 1号, pp. 24-28, 20250301
  7. Carbon monoxide alleviates endotoxin-induced acute lung injury via NADPH oxidase inhibition in macrophages and neutrophils, Biochemical Pharmacology, 233巻, 20250301
  8. Simulated achievement rate of β-lactams/nacubactam treatment in humans using instantaneous MIC-based PK/PD analysis, Journal of Antimicrobial Chemotherapy, 80巻, 2号, pp. 547-553, 20250201
  9. Treatment success prediction in patients with methicillin-resistant coagulase-negative staphylococci infections, using vancomycin AUC24/MIC ratio: a multicentre retrospective cohort study, Journal of Antimicrobial Chemotherapy, 80巻, 2号, pp. 538-546, 20250201
  10. Development of a pharmacokinetic/pharmacodynamic evaluation model for osteomyelitis and usefulness of tedizolid as an alternative to vancomycin against MRSA osteomyelitis, Journal of Pharmacy and Pharmacology, 77巻, 2号, pp. 291-298, 20250201
  11. One-Step Maleimide-Based Dual Functionalization of Protein N-Termini, Angewandte Chemie International Edition, 64巻, 5号, 20250127
  12. Influence factors of metronidazole-related CNS disorders: an analysis of the Japan adverse drug event report and FDA adverse event reporting system, Expert Opinion on Drug Safety, 20250101
  13. SARS-CoV-2 mRNA vaccine-related myocarditis and pericarditis: An analysis of the Japanese Adverse Drug Event Report database, Journal of Infection and Chemotherapy, 31巻, 1号, 20250101
  14. Investigating the hypothermic effects of fluoroquinolone antimicrobials on non-bacterial fever model mice, Journal of Pharmaceutical Health Care and Sciences, 10巻, 1号, 20241201
  15. Identification of Patients Who Require Two-Point Blood Sampling for the Peak and Trough Values Rather Than One-Point Blood Sampling for the Trough Value for the Evaluation of AUC of Vancomycin Using Bayesian Estimation, Pharmaceutical Research, 41巻, 11号, pp. 2161-2171, 20241101
  16. Hydrosulphide-methaemoglobin-albumin cluster: a hydrogen sulphide donor, Journal of Materials Chemistry B, 12巻, 44号, pp. 11515-11522, 20241014
  17. T-cell immunosuppression in sepsis is augmented by sciatic denervation-induced skeletal muscle atrophy, FEBS Letters, 598巻, 20号, pp. 2581-2591, 20241001
  18. Carbon monoxide-loaded red blood cells ameliorate metabolic dysfunction-associated steatohepatitis progression via enhancing AMP-activated protein kinase activity and inhibiting Kupffer cell activation, Redox Biology, 76巻, 20241001
  19. Carbon monoxide-loaded cell therapy as an exercise mimetic for sarcopenia treatment, Free Radical Biology and Medicine, 220巻, pp. 67-77, 20240801
  20. Antimicrobial Stewardship of Oral Third-Generation Cephalosporins in Community Pharmacy: A Single-Center Quasi-Experimental Study, Biological and Pharmaceutical Bulletin, 47巻, 8号, pp. 1447-1451, 20240801
  21. Predictive Value of Vancomycin AUC24/MIC Ratio for 30-day Mortality in Patients with Severe or Complicated Methicillin-Resistant Staphylococcus aureus Infections: A Multicenter Retrospective Study, Pharmaceutical Research, 41巻, 7号, pp. 1381-1389, 20240701
  22. Relationship between nephrotoxicity and area under the concentration-time curve of vancomycin in critically ill patients: a multicenter retrospective study, Microbiology Spectrum, 12巻, 7号, 20240701
  23. Anti-edematous effects of epinastine, cetirizine and its enantiomers in λ-carrageenan-induced edema in rat hind paw, Pharmazie, 79巻, 6号, pp. 98-100, 20240601
  24. Dual delivery of carbon monoxide and doxorubicin using haemoglobin-albumin cluster: proof of concept for well-tolerated cancer therapy, Journal of Materials Chemistry B, 12巻, 23号, pp. 5600-5608, 20240507
  25. Direct comparison of anti-inflammatory effects of 14-, 15-, and 16-membered macrolide antibiotics in experimental inflammation model induced by carrageenan in rats, Pharmazie, 79巻, 3-5号, pp. 64-66, 20240501
  26. Flowchart for predicting achieving the target area under the concentration-time curve of vancomycin in critically ill Japanese patients: A multicenter retrospective study, Journal of Infection and Chemotherapy, 30巻, 4号, pp. 329-336, 20240401
  27. Preparation and in Vitro Characterization of Fatty-Acid Modified Pirarubicin Nanosuspensions Stabilized by Albumin, Chemical and Pharmaceutical Bulletin, 72巻, 1号, pp. 21-27, 20240101
  28. Carbon Monoxide Alleviates Post-ischemia–reperfusion Skeletal Muscle Injury and Systemic Inflammation, Biological and Pharmaceutical Bulletin, 47巻, 4号, pp. 868-871, 20240101
  29. Qualitative and quantitative status of cytochrome P450s after the administration of a liposomal platelet substitute in rat liver, Xenobiotica, 54巻, 9号, pp. 624-628, 20240101
  30. Polyoxazoline-Conjugated l-Asparaginase: An Antibody-Production-Free Therapeutic Agent for Acute Lymphoblastic Leukemia, ACS Applied Bio Materials, 6巻, 12号, pp. 5789-5797, 20231218
  31. Elucidating the binding properties of methemoglobin in red blood cell to cyanide, hydrosulfide, and azide ions using artificial red blood cell, Toxicology and Applied Pharmacology, 481巻, 20231215
  32. Oral teicoplanin administration suppresses recurrence of Clostridioides difficile infection: Proof of concept, Anaerobe, 84巻, 20231201
  33. Polysarcosine-Coated liposomes attenuating immune response induction and prolonging blood circulation, Journal of Colloid and Interface Science, 651巻, pp. 273-283, 20231201
  34. Polyoxazoline-conjugated porcine serum albumin as an artificial plasma expander for dogs, Scientific Reports, 13巻, 1号, 20231201
  35. The anti-inflammatory effect of tedizolid on carrageenan-induced footpad edema rat model, Journal of Infection and Chemotherapy, 29巻, 11号, pp. 1088-1090, 20231101
  36. Pharmaceutical stability of methemoglobin-albumin cluster as an antidote for hydrogen sulfide poisoning after one-year storage in freeze-dried form, International Journal of Pharmaceutics, 645巻, 20231015
  37. A combination of 5/6-nephrectomy and unilateral ureteral obstruction model accelerates progression of remote organ fibrosis in chronic kidney disease, FASEB Bioadvances, 5巻, 10号, pp. 377-394, 20231001
  38. In vivo Pharmacokinetic/Pharmacodynamic Analysis of the Efficacy of the Cefepime/Nacubactam Combination Against β-Lactamase-Producing Enterobacterales based on the Instantaneous MIC Concept, Pharmaceutical Research, 40巻, 10号, pp. 2423-2431, 20231001
  39. Carbon Monoxide-Loaded Red Blood Cell Prevents the Onset of Cisplatin-Induced Acute Kidney Injury, Antioxidants, 12巻, 9号, 20230901
  40. Antimicrobial Efficacy Evaluations of Metronidazole against Clostridioides difficile Infection using Fecal Pharmacokinetic and Pharmacodynamic Analyses, Pharmaceutical Research, 40巻, 7号, pp. 1799-1806, 20230701
  41. In vivo Pharmacokinetics/Pharmacodynamics Profiles for Appropriate Doses of Cefditoren pivoxil against S. pneumoniae in Murine Lung-Infection Model, Pharmaceutical Research, 40巻, 7号, pp. 1789-1797, 20230701
  42. Anti-inflammatory actions of expectorants in a rat carrageenan-induced footpad edema model, Pharmazie, 78巻, 6-7号, pp. 86-88, 20230701
  43. Pharmaceutical Integrity of Lyophilized Methemoglobin-Albumin Clusters after Reconstitution, ACS Omega, 8巻, 25号, pp. 22589-22595, 20230627
  44. Optimal therapeutic recommendation for Clostridioides difficile infection in pediatric and adolescent populations: a systematic review and meta-analysis, European Journal of Pediatrics, 182巻, 6号, pp. 2673-2681, 20230601
  45. Fecal pharmacokinetics/pharmacodynamics characteristics of fidaxomicin and vancomycin against Clostridioides difficile infection elucidated by in vivo feces-based infectious evaluation models, Clinical Microbiology and Infection, 29巻, 5号, pp. 616-622, 20230501
  46. Methemoglobin-albumin clusters for cyanide detoxification, Toxicology and Applied Pharmacology, 466巻, 20230501
  47. Comparison of the efficacy and safety of standard- and high-dose daptomycin: A systematic review and meta-analysis, British Journal of Clinical Pharmacology, 89巻, 4号, pp. 1291-1303, 20230401
  48. Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae, Journal of Antimicrobial Chemotherapy, 78巻, 4号, pp. 991-999, 20230401
  49. SCIATIC DENERVATION-INDUCED SKELETAL MUSCLE ATROPHY IS ASSOCIATED WITH PERSISTENT INFLAMMATION AND INCREASED MORTALITY DURING SEPSIS, Shock, 59巻, 3号, pp. 417-425, 20230301
  50. The G protein-coupled receptor ligand apelin-13 ameliorates skeletal muscle atrophy induced by chronic kidney disease, Journal of Cachexia Sarcopenia and Muscle, 14巻, 1号, pp. 553-564, 20230201
  51. Differences in Pharmacokinetic/Pharmacodynamic Parameters of Tedizolid Against VRE and MRSA, Pharmaceutical Research, 40巻, 1号, pp. 187-196, 20230101
  52. Analysis of Risk Factors for Developing Tuberculosis in Patients Who Received Prophylactic Latent Tuberculosis Infection Treatment with Experience of Biologic Medications, Biological and Pharmaceutical Bulletin, 46巻, 12号, pp. 1832-1837, 20230101
  53. Safety of linezolid in patients with decreased renal function and trough monitoring: a systematic review and meta-analysis, BMC Pharmacology and Toxicology, 23巻, 1号, 20221201
  54. Analysis of adverse drug events in pulmonary Mycobacterium avium complex disease using spontaneous reporting system, BMC Infectious Diseases, 22巻, 1号, 20221201
  55. Ceftazidime encephalopathy developed without the elevation of cerebrospinal fluid concentration of ceftazidime: A case report of two cases, Journal of Infection and Chemotherapy, 28巻, 12号, pp. 1667-1671, 20221201
  56. In vitro effects of diazabicyclooctane β-lactamase inhibitors relebactam and nacubactam against three subspecies of Mycobacterium abscessus complex, International Journal of Antimicrobial Agents, 60巻, 5-6号, 20221101
  57. Oral fidaxomicin versus vancomycin for the treatment of Clostridioides difficile infection: A systematic review and meta-analysis of randomized controlled trials, Journal of Infection and Chemotherapy, 28巻, 11号, pp. 1536-1545, 20221101
  58. Efficacy of surgical skin preparation with chlorhexidine in alcohol according to the concentration required to prevent surgical site infection: Meta-Analysis, Bjs Open, 6巻, 5号, 20221001
  59. Methemoglobin-albumin clusters for the treatment of hydrogen sulfide intoxication, Journal of Controlled Release, 349巻, pp. 304-314, 20220901
  60. Liposomal methemoglobin as a potent antidote for hydrogen sulfide poisoning, Toxicology and Applied Pharmacology, 450巻, 20220901
  61. Exploring the Factors Affecting the Transferability of Vancomycin to Cerebrospinal Fluid in Postoperative Neurosurgical Patients with Bacterial Meningitis, Biological and Pharmaceutical Bulletin, 45巻, 9号, pp. 1398-1402, 20220901
  62. Single-Step N-Terminal Modification of Proteins via a Bio-Inspired Copper(II)-Mediated Aldol Reaction, Chemistry A European Journal, 28巻, 47号, 20220822
  63. Trimethoxy Trityl Groups as a Potent Substituent for Anti-cancer Cytidine Analog Prodrugs, Journal of Pharmaceutical Sciences, 111巻, 8号, pp. 2201-2209, 20220801
  64. Influences of protein levels on the cerebrospinal fluid distribution of ceftazidime & ceftriaxone in the cerebrospinal fluid of patients with inflamed meningitis, Journal of Infection and Chemotherapy, 28巻, 8号, pp. 1216-1219, 20220801
  65. A bioinspired carbon monoxide delivery system prevents acute kidney injury and the progression to chronic kidney disease, Redox Biology, 54巻, 20220801
  66. Target Therapeutic Ranges of Anti-MRSA Drugs, Linezolid, Tedizolid and Daptomycin, and the Necessity of TDM, Biological and Pharmaceutical Bulletin, 45巻, 7号, pp. 824-833, 20220701
  67. 人口動態統計に基づいたセルフメディケーション税制に関する実態調査と課題抽出, 医療薬学, 48巻, 7号, pp. 276-283, 20220701
  68. Augmented Clearance of Nivolumab Is Associated with Renal Functions in Chronic Renal Disease Model Rats, Drug Metabolism and Disposition, 50巻, 6号, pp. 822-826, 20220601
  69. Oxidized liposomal artificial red blood cells rescue azide-poisoned mice from lethal toxidrome by recovering cytochrome c oxidase activity, Journal of Drug Delivery Science and Technology, 71巻, 20220501
  70. Incidence of elevated creatine phosphokinase between daptomycin alone and concomitant daptomycin and statins: A systematic review and meta-analysis, British Journal of Clinical Pharmacology, 88巻, 5号, pp. 1985-1998, 20220501
  71. Efficacy and Safety of Daptomycin versus Vancomycin for Bacteremia Caused by Methicillin-Resistant Staphylococcus aureus with Vancomycin Minimum Inhibitory Concentration > 1 µg/mL: A Systematic Review and Meta-Analysis, Pharmaceutics, 14巻, 4号, 20220401
  72. In Vitro and In Vivo Assessment of Atemoya Fruit (Annona atemoya) for Food–Drug Interactions, European Journal of Drug Metabolism and Pharmacokinetics, 47巻, 2号, pp. 177-185, 20220301
  73. Neurotoxicity associated with colistin methanesulfonate treatment is enhanced by concomitant sevoflurane inhalation, Toxicology Reports, 9巻, pp. 1255-1260, 20220101
  74. An in-vitro comparative study of the binding of caspofungin and micafungin to plasma proteins, Journal of Pharmacy and Pharmacology, 74巻, 1号, pp. 88-93, 20220101
  75. Bioinspired carbon monoxide delivery using artificial blood attenuates the progression of obliterative bronchiolitis via suppression of macrophage activation by IL-17A, European Journal of Pharmaceutics and Biopharmaceutics, 170巻, pp. 43-51, 20220101
  76. Liposomal artificial red blood cell-based carbon monoxide donor is a potent renoprotectant against cisplatin-induced acute kidney injury, Pharmaceutics, 14巻, 1号, 20220101
  77. Impact of rifampicin on the pharmacokinetics of clarithromycin and 14-hydroxy clarithromycin in patients with multidrug combination therapy for pulmonary Mycobacterium avium complex infection, Journal of Infection and Chemotherapy, 28巻, 1号, pp. 61-66, 20220101
  78. Research of storable and ready-to-use artificial red blood cells (hemoglobin vesicles) for emergency medicine and other clinical applications, Frontiers in Medical Technology, 4巻, 20220101
  79. Long-term pharmaceutical stability of liposome-encapsulated methemoglobin as an antidote for cyanide poisoning, International Journal of Pharmaceutics, 610巻, 20211215
  80. The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing, BMC Infectious Diseases, 21巻, 1号, 20211201
  81. Identification of Risk Factors for Daptomycin-Associated Creatine Phosphokinase Elevation and Development of a Risk Prediction Model for Incidence Probability, Open Forum Infectious Diseases, 8巻, 12号, 20211201
  82. Rational dosage regimens for cephalothin and cefazolin using pharmacokinetics and pharmacodynamics analysis in healthy horses, Equine Veterinary Journal, 53巻, 6号, pp. 1239-1249, 20211101
  83. Population pharmacokinetic analysis and dosing optimization of prophylactic fluconazole in japanese patients with hematological malignancy, Journal of Fungi, 7巻, 11号, 20211101
  84. Cefmetazole as an Alternative to Carbapenems Against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Infections Based on In Vitro and In Vivo Pharmacokinetics/Pharmacodynamics Experiments, Pharmaceutical Research, 38巻, 11号, pp. 1839-1846, 20211101
  85. Retrospective study of the efficacy and safety of metronidazole and vancomycin for Clostridioides difficile infection, Journal of Infection and Chemotherapy, 27巻, 10号, pp. 1407-1412, 20211001
  86. Liposome-encapsulated methemoglobin as an antidote against cyanide poisoning, Journal of Controlled Release, 337巻, pp. 59-70, 20210910
  87. Different intra-cerebrospinal distribution of linezolid in patients with inflammatory meningitis, International Journal of Infectious Diseases, 110巻, pp. 382-384, 20210901
  88. Species distribution of candidemia and their susceptibility in a single japanese university hospital: Prior micafungin use affects the appearance of candida parapsilosis and elevation of micafungin mics in non‐parapsilosis candida species, Journal of Fungi, 7巻, 8号, 20210801
  89. セルフメディケーション税制に対する新人薬局薬剤師の認知・見解実態把握調査, 医療薬学, 47巻, 7号, pp. 358-363, 20210701
  90. Pharmacokinetics of 4′-cyano-2′-deoxyguanosine, a novel nucleoside analog inhibitor of the resistant hepatitis B virus, in a rat model of chronic kidney disease, Journal of Infection and Chemotherapy, 27巻, 5号, pp. 702-706, 20210501
  91. The optimal trough-guided monitoring of vancomycin in children: Systematic review and meta-analyses, Journal of Infection and Chemotherapy, 27巻, 5号, pp. 781-785, 20210501
  92. 健康セミナー参加者におけるセルフメディケーション税制に関する実態調査と税制改定に向けた課題の抽出, 医療薬学, 47巻, 5号, pp. 256-263, 20210501
  93. Multivalent cation and polycation polymer preparations influence pharmacokinetics of dolutegravir via chelation-type drug interactions, Drug Metabolism and Pharmacokinetics, 37巻, 20210401
  94. When albumin meets liposomes: A feasible drug carrier for biomedical applications, Pharmaceuticals, 14巻, 4号, 20210401
  95. Remdesivir for the treatment of coronavirus COVID-19: A meta-analysis of randomised controlled trials, Journal of Global Antimicrobial Resistance, 24巻, pp. 81-82, 20210301
  96. 院内製剤酢酸含有軟膏の保存安定性評価, 医療薬学, 47巻, 3号, pp. 171-177, 20210301
  97. Stability of antimicrobial agents in an elastomeric infusion pump used for outpatient parenteral antimicrobial therapy, International Journal of Infectious Diseases, 103巻, pp. 464-468, 20210201
  98. Possible role of electrolytes on the formation of precipitates during the infusion of nafamostat mesilate in hemodialysis, Biological and Pharmaceutical Bulletin, 44巻, 2号, pp. 259-265, 20210201
  99. Use of an alternative signature peptide during development of a LC-MS/MS assay of plasma nivolumab levels applicable for multiple species, Journal of Chromatography B Analytical Technologies in the Biomedical and Life Sciences, 1162巻, 20210101
  100. Pharmacokinetics/Pharmacodynamics Evaluation of Flomoxef against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli In Vitro and In Vivo in a Murine Thigh Infection Model, Pharmaceutical Research, 38巻, 1号, pp. 27-35, 20210101
  101. Population Pharmacokinetic Analysis and Dosing Optimization Based on Unbound Daptomycin Concentration and Cystatin C in Nonobese Elderly Patients with Hypoalbuminemia and Chronic Kidney Disease, Pharmaceutical Research, 20210101
  102. Development of a bioactive gas delivery strategy based on biomimetic red blood cells for the treatment of intractable diseases 13th Young Scientist Award, Japan Society of DDS, Drug Delivery System, 36巻, 4号, pp. 300-306, 20210101
  103. Pharmaceutical technology innovation strategy based on the function of blood transport proteins as DDS carriers for the treatment of intractable disorders and cancer, Biological and Pharmaceutical Bulletin, 43巻, 12号, pp. 1815-1822, 20201201
  104. Echinocandins versus non-echinocandins for the treatment of invasive candidiasis: A meta-analysis of randomized controlled trials, Journal of Infection and Chemotherapy, 26巻, 11号, pp. 1164-1176, 20201101
  105. Azoles versus conventional amphotericin B for the treatment of candidemia: A meta-analysis of randomized controlled trials, Journal of Infection and Chemotherapy, 26巻, 11号, pp. 1232-1236, 20201101
  106. Hepatic Cytochrome P450 Profiles in Hemorrhagic Shock Model Rats After Transfusion With Stored Red Blood Cells, Journal of Pharmaceutical Sciences, 109巻, 11号, pp. 3490-3495, 20201101
  107. Concurrent administration with multivalent metal cation preparations or polycationic polymer preparations inhibits the absorption of raltegravir via its chelation, Journal of Pharmacy and Pharmacology, 72巻, 10号, pp. 1361-1369, 20201001
  108. Assessing cytochrome P450-based drug-drug interactions with hemoglobin-vesicles, an artificial red blood cell preparation, in healthy rats, Drug Metabolism and Pharmacokinetics, 35巻, 5号, pp. 425-431, 20201001
  109. Evaluation of cytochrome P450-based drug metabolism in hemorrhagic shock rats that were transfused with native and an artificial red blood cell preparation, Hemoglobin-vesicles, Drug Metabolism and Pharmacokinetics, 35巻, 5号, pp. 417-424, 20201001
  110. Characterization of the Interaction of Daptomycin With Site II on Human Serum Albumin, Journal of Pharmaceutical Sciences, 109巻, 9号, pp. 2919-2924, 20200901
  111. Pharmacokinetic properties of orally administered 4′-Cyano-2′-deoxyguanosine, a novel nucleoside analog inhibitor of the hepatitis B virus, in viral liver injury model rats, Biological and Pharmaceutical Bulletin, 43巻, 9号, pp. 1426-1429, 20200901
  112. Evasion of the accelerated blood clearance phenomenon by polysarcosine coating of liposomes, Journal of Controlled Release, 322巻, pp. 209-216, 20200610
  113. In vivo evaluation of drug dialyzability in a rat model of hemodialysis, Plos One, 15巻, 6号, 20200601
  114. Effects of arterial hemorrhage speed on the blood coagulation/fibrinolysis system and hemodynamics in rats, Blood Coagulation and Fibrinolysis, 31巻, 3号, pp. 198-206, 20200401
  115. Support for fungal infection treatment mediated by pharmacist-led antifungal stewardship activities, Journal of Infection and Chemotherapy, 26巻, 3号, pp. 272-279, 20200301
  116. Processing grapefruit juice with γ-cyclodextrin attenuates its inhibitory effect on cytochrome P450 3A activity, Journal of Pharmacy and Pharmacology, 72巻, 3号, pp. 356-363, 20200301
  117. Carbon monoxide rescues the developmental lethality of experimental rat models of rhabdomyolysis-induced acute kidney injury, Journal of Pharmacology and Experimental Therapeutics, 372巻, 3号, pp. 355-365, 20200301
  118. Cell uptake and anti-tumor effect of liposomes containing encapsulated paclitaxel-bound albumin against breast cancer cells in 2D and 3D cultured models, Journal of Drug Delivery Science and Technology, 55巻, 20200201
  119. The charm of protein for drug development, Yakugaku Zasshi, 140巻, 2号, pp. 139-140, 20200201
  120. Strategy of drug development based on the bioactive gas-carrying capacity of hemoglobin, Yakugaku Zasshi, 140巻, 2号, pp. 141-146, 20200201
  121. Use of hemoglobin for delivering exogenous carbon monoxide in medicinal applications, Current Medicinal Chemistry, 27巻, 18号, pp. 2949-2963, 20200101
  122. Characterization of bovine lactoferrin nanoparticle prepared by desolvation technique, Chemical and Pharmaceutical Bulletin, 68巻, 8号, pp. 766-772, 20200101
  123. Experimental verification of factors influencing calcium salt formation based on a survey of the development of ceftriaxone-induced gallstone-related disorder, Journal of Infection and Chemotherapy, 25巻, 12号, pp. 972-978, 20191201
  124. α1-Acid Glycoprotein Has the Potential to Serve as a Biomimetic Drug Delivery Carrier for Anticancer Agents, Journal of Pharmaceutical Sciences, 108巻, 11号, pp. 3592-3598, 20191101
  125. Enhanced dissolution and oral bioavailability of praziquantel by emulsification with human serum albumin followed by spray drying, European Journal of Pharmaceutical Sciences, 139巻, 20191101
  126. Evaluation for optimal dosing of vancomycin in patients with different physical types, Journal of Infection and Chemotherapy, 25巻, 9号, pp. 735-737, 20190901
  127. Investigation of anti-tumor effect of doxorubicin-loaded human serum albumin nanoparticles prepared by a desolvation technique, Cancer Chemotherapy and Pharmacology, 83巻, 6号, pp. 1113-1120, 20190601
  128. ヘパリン類似物質含有製剤の選択に有用な情報構築に関する検討, 日本老年薬学会雑誌, 2巻, 2号, pp. 19-26, 20190601
  129. Preparation, Characterization, and in Vitro/in Vivo Evaluation of Paclitaxel-Bound Albumin-Encapsulated Liposomes for the Treatment of Pancreatic Cancer, ACS Omega, 4巻, 5号, pp. 8693-8700, 20190517
  130. Pharmacokinetic and pharmacodynamic studies of pregabalin suppositories based on pharmacological research, Journal of Pharmacy and Pharmacology, 71巻, 5号, pp. 746-752, 20190501
  131. Further Evidence Regarding the Important Role of Chlorine Atoms of Aripiprazole on Binding to the Site II Area of Human Albumin, Journal of Pharmaceutical Sciences, 108巻, 5号, pp. 1890-1895, 20190501
  132. Age-associated theophylline metabolic activity corresponds to the ratio of 1,3-dimethyluric acid to theophylline in mice, Biological and Pharmaceutical Bulletin, 42巻, 8号, pp. 1423-1427, 20190101
  133. Evaluation of the expression time of ganciclovir-induced adverse events using JADER and FAERS, Biological and Pharmaceutical Bulletin, 42巻, 11号, pp. 1799-1804, 20190101
  134. Oral vancomycin versus metronidazole for the treatment of Clostridioides difficile infection: Meta-analysis of randomized controlled trials, Journal of Infection and Chemotherapy, 24巻, 11号, pp. 907-914, 20181101
  135. Analysis of the Binding of Aripiprazole to Human Serum Albumin: The Importance of a Chloro-Group in the Chemical Structure, ACS Omega, 3巻, 10号, pp. 13790-13797, 20181022
  136. In vivo drug delivery efficiency of albumin-encapsulated liposomes as hydrophobic drug carriers, Journal of Drug Delivery Science and Technology, 47巻, pp. 62-66, 20181001
  137. Metal-catalyzed oxidation of human serum albumin does not alter the interactive binding to the two principal drug binding sites, Biochemistry and Biophysics Reports, 14巻, pp. 155-160, 20180701
  138. Pharmacokinetics studies of 4′-cyano-2′-deoxyguanosine, a potent inhibitor of the hepatitis B virus, in rats, Journal of Pharmacy and Pharmacology, 70巻, 6号, pp. 723-731, 20180601
  139. Pharmacokinetic properties of a novel inosine analog, 40-cyano-20-deoxyinosine, after oral administration in rats, Plos One, 13巻, 6号, 20180601
  140. Development of kupffer cell targeting type-i interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions, Drug Delivery, 25巻, 1号, pp. 1067-1077, 20180424
  141. Albumin-Encapsulated Liposomes: A Novel Drug Delivery Carrier With Hydrophobic Drugs Encapsulated in the Inner Aqueous Core, Journal of Pharmaceutical Sciences, 107巻, 1号, pp. 436-445, 20180101
  142. Preparation and in vitro analysis of human serum albumin nanoparticles loaded with anthracycline derivatives, Chemical and Pharmaceutical Bulletin, 66巻, 4号, pp. 382-390, 20180101
  143. Biomimetic carbon monoxide delivery based on hemoglobin vesicles ameliorates acute pancreatitis in mice via the regulation of macrophage and neutrophil activity, Drug Delivery, 25巻, 1号, pp. 1266-1274, 20180101
  144. Safety of nanoparticles based on albumin-polymer conjugates as a carrier of nucleotides for pancreatic cancer therapy, Journal of Materials Chemistry B, 6巻, 39号, pp. 6278-6287, 20180101
  145. Benzbromarone attenuates oxidative stress in angiotensin II- and salt-induced hypertensive model rats, Oxidative Medicine and Cellular Longevity, 2018巻, 20180101
  146. Safety evaluation of cellular-type artificial blood based on pharmacokinetic analysis and its use in medical gas delivery, Yakugaku Zasshi, 138巻, 11号, pp. 1381-1389, 20180101
  147. Species Differences in the Binding of Sodium 4-Phenylbutyrate to Serum Albumin, Journal of Pharmaceutical Sciences, 106巻, 9号, pp. 2860-2867, 20170901
  148. The Use of Hemoglobin Vesicles for Delivering Medicinal Gas for the Treatment of Intractable Disorders, Journal of Pharmaceutical Sciences, 106巻, 9号, pp. 2392-2400, 20170901
  149. Long chain fatty acids alter the interactive binding of ligands to the two principal drug binding sites of human serum albumin, Plos One, 12巻, 6号, 20170601
  150. Structural and biological characterization of Fe3O4-loaded spherical and tubular liposomes for use in drug delivery systems, Japanese Journal of Applied Physics, 56巻, 5号, 20170501
  151. Locational analysis of glutathione in liposomes by using small-angle X-ray scattering, Chemistry Letters, 46巻, 2号, pp. 185-187, 20170101
  152. The binding of silibinin, the main constituent of silymarin, to site i on human serum albumin, Biological and Pharmaceutical Bulletin, 40巻, 3号, pp. 310-317, 20170101
  153. Recombinant human serum albumin containing 3 copies of domain I, Has significant in vitro antioxidative capacity compared to the wild-type, Biological and Pharmaceutical Bulletin, 40巻, 10号, pp. 1813-1817, 20170101
  154. Carbon monoxide-bound hemoglobin vesicles ameliorate multiorgan injuries induced by severe acute pancreatitis in mice by their anti-inflammatory and antioxidant properties, International Journal of Nanomedicine, 11巻, pp. 5611-5620, 20161027
  155. Long-term stored hemoglobin-vesicles, a cellular type of hemoglobin-based oxygen carrier, has resuscitative effects comparable to that for fresh red blood cells in a rat model with massive hemorrhage without post-transfusion lung injury, Plos One, 11巻, 10号, 20161001
  156. Evaluation of a new type of nano-sized carbon monoxide donor on treating mice with experimentally induced colitis, Journal of Controlled Release, 234巻, pp. 49-58, 20160728
  157. Tyrosine411 and Arginine410 of Human Serum Albumin Play an Important Role in the Binding of Sodium 4-Phenylbutyrate to Site II, Journal of Pharmaceutical Sciences, 105巻, 6号, pp. 1987-1994, 20160601
  158. Antioxidant and renoprotective activity of 2-hydroxypropyl-β-cyclodextrin in nephrectomized rats, Journal of Pharmacy and Pharmacology, 68巻, 5号, pp. 608-614, 20160501
  159. Comparison of Posttranslational Modification and the Functional Impairment of Human Serum Albumin in Commercial Preparations, Journal of Pharmaceutical Sciences, 105巻, 3号, pp. 1043-1049, 20160301
  160. Influence of molecular structure on O2-binding properties and blood circulation of hemoglobin?albumin clusters, Plos One, 11巻, 2号, 20160201
  161. Pharmacokinetic Properties of Single and Repeated Injection of Liposomal Platelet Substitute in a Rat Model of Red Blood Cell Transfusion-Induced Dilutional Thrombocytopenia, Journal of Pharmaceutical Sciences, 104巻, 11号, pp. 3968-3976, 20151101
  162. Artificial oxygen carriers rescue placental hypoxia and improve fetal development in the rat pre-eclampsia model, Scientific Reports, 5巻, 20151016
  163. Kupffer cell inactivation by carbon monoxide bound to red blood cells preserves hepatic cytochrome P450 via anti-oxidant and anti-inflammatory effects exerted through the HMGB1/TLR-4 pathway during resuscitation from hemorrhagic shock, Biochemical Pharmacology, 97巻, 3号, pp. 310-319, 20151001
  164. Biological responsiveness and metabolic performance of liposome-encapsulated hemoglobin (hemoglobin-vesicles) in apolipoprotein E-deficient mice after massive intravenous injection, Biological and Pharmaceutical Bulletin, 38巻, 10号, pp. 1606-1616, 20151001
  165. Establishment of a model of acetaminophen-induced hepatotoxicity in different weekly-aged ICR mice, Laboratory Animals, 49巻, 4号, pp. 294-301, 20151001
  166. Effect of Repeated Injections of Adenosine Diphosphate-Encapsulated Liposomes Coated with a Fibrinogen γ-Chain Dodecapeptide Developed as a Synthetic Platelet Substitute on Accelerated Blood Clearance in a Healthy and an Anticancer Drug-Induced Thrombocytopenia Rat Model, Journal of Pharmaceutical Sciences, 104巻, 9号, pp. 3084-3091, 20150901
  167. Potential use of biological proteins for liver failure therapy, Pharmaceutics, 7巻, 3号, pp. 255-274, 20150831
  168. Safety Evaluation of Hemoglobin-Albumin Cluster "HemoAct" as a Red Blood Cell Substitute, Scientific Reports, 5巻, 20150729
  169. Direct radical scavenging activity of benzbromarone provides beneficial antioxidant properties for hyperuricemia treatment, Biological and Pharmaceutical Bulletin, 38巻, 3号, pp. 487-492, 20150301
  170. Polythiol-containing, recombinant mannosylated-albumin is a superior CD68+/CD206+ Kupffer cell-targeted nanoantioxidant for treatment of two acute hepatitis models, Journal of Pharmacology and Experimental Therapeutics, 352巻, 2号, pp. 244-257, 20150101
  171. Cross-linked human serum albumin dimer has the potential for use as a plasma-retaining agent for the fatty acid-conjugated antidiabetic drugs, Journal of Pharmacy and Pharmacology, 67巻, 2号, pp. 255-263, 20150101
  172. Amino acids of importance for the antioxidant activity of human serum albumin as revealed by recombinant mutants and genetic variants, Life Sciences, 134巻, 1号, pp. 36-41, 20150101
  173. An evaluation of novel biological activity in a crude extract from Hemerocallis fulva L. var. sempervirens M. Hotta, Natural Product Research, 28巻, 23号, pp. 2211-2213, 20141205
  174. False tacrolimus concentrations measured by antibody-conjugated magnetic immunoassay in liver transplant patient: 2 case reports and literature review, Experimental and Clinical Transplantation, 12巻, 5号, pp. 474-478, 20141001
  175. Therapeutic impact of erythropoietin-encapsulated liposomes targeted to bone marrow on renal anemia, Molecular Pharmaceutics, 11巻, 11号, pp. 4238-4248, 20140925
  176. Carbon monoxide-bound hemoglobin-vesicles for the treatment of bleomycin-induced pulmonary fibrosis, Biomaterials, 35巻, 24号, pp. 6553-6562, 20140101
  177. Carbon monoxide-bound red blood cell resuscitation ameliorates hepatic injury induced by massive hemorrhage and red blood cell resuscitation via hepatic cytochrome P450 protection in hemorrhagic shock rats, Journal of Pharmaceutical Sciences, 103巻, 7号, pp. 2199-2206, 20140101
  178. Carbamazepine-imatinib interaction in a child with chronic myeloid leukemia, Pediatrics International, 56巻, 4号, pp. e33-e36, 20140101
  179. Effect of albumin on transthyretin and amyloidogenic transthyretin Val30Met disposition and tissue deposition in familial amyloidotic polyneuropathy, Life Sciences, 93巻, 25-26号, pp. 1017-1022, 20131218
  180. Pharmacokinetic study of the structural components of adenosine diphosphate-encapsulated liposomes coated with fibrinogen g-chain dodecapeptide as a synthetic platelet substitutes, Drug Metabolism and Disposition, 41巻, 8号, pp. 1584-1591, 20130801
  181. A reduced linezolid dosage maintains favorable efficacy with minimal hematologic toxicity in a methicillin-resistant Staphylococcus aureus-infected patient with renal insufficiency, Scandinavian Journal of Infectious Diseases, 45巻, 1号, pp. 77-80, 20130101
  182. Carbon monoxide-bound red blood cells protect red blood cell transfusion-induced hepatic cytochrome P450 impairment in hemorrhagic-shock rats, Drug Metabolism and Disposition, 41巻, 1号, pp. 141-148, 20130101
  183. Pharmacokinetic Study of Adenosine Diphosphate-Encapsulated Liposomes Coated with Fibrinogen γ-Chain Dodecapeptide as a Synthetic Platelet Substitute in an Anticancer Drug-Induced Thrombocytopenia Rat Model, Journal of Pharmaceutical Sciences, 102巻, 10号, pp. 3852-3859, 20130101
  184. Effect of acetaminophen on the progression of renal damage in adenine induced renal failure model rats, Life Sciences, 91巻, 25-26号, pp. 1304-1308, 20121217
  185. Liposome-encapsulated hemoglobin (hemoglobin-vesicle) is not transferred from mother to fetus at the late stage of pregnancy in the rat model, Life Sciences, 91巻, 11-12号, pp. 420-428, 20121005
  186. Carvedilol enhances mesenchymal stem cell therapy for myocardial infarction via inhibition of caspase-3 expression, Journal of Pharmacology and Experimental Therapeutics, 343巻, 1号, pp. 62-71, 20121001
  187. Pharmaceutical aspects of the recombinant human serum albumin dimer: Structural characteristics, biological properties, and medical applications, Journal of Pharmaceutical Sciences, 101巻, 9号, pp. 3033-3046, 20120101
  188. Biological characteristics of two lysines on human serum albumin in the high-affinity binding of 4Z,15Z-bilirubin-IXα revealed by phage display, FEBS Journal, 278巻, 21号, pp. 4100-4111, 20111101
  189. Human serum albumin-thioredoxin fusion protein with long blood retention property is effective in suppressing lung injury, Journal of Controlled Release, 154巻, 2号, pp. 189-195, 20110905
  190. Pharmacokinetic properties of hemoglobin vesicles as a substitute for red blood cells, Drug Metabolism Reviews, 43巻, 3号, pp. 362-373, 20110801
  191. Repeated injection of high doses of hemoglobin-encapsulated liposomes (hemoglobin vesicles) induces accelerated blood clearance in a hemorrhagic shock rat model, Drug Metabolism and Disposition, 39巻, 3号, pp. 484-489, 20110301
  192. Alteration in the pharmacokinetics of hemoglobin-vesicles in a rat model of chronic liver cirrhosis is associated with kupffer cell phagocyte activity, Journal of Pharmaceutical Sciences, 100巻, 2号, pp. 775-783, 20110101
  193. Fluid resuscitation with hemoglobin vesicles prevents Escherichia coli growth via complement activation in a hemorrhagic shock rat model, Journal of Pharmacology and Experimental Therapeutics, 337巻, 1号, pp. 201-208, 20110101
  194. Superior plasma retention of a cross-linked human serum albumin dimer in nephrotic rats as a new type of plasma expander, Drug Metabolism and Disposition, 38巻, 12号, pp. 2124-2129, 20101201
  195. Hepatically-metabolized and -excreted artificial oxygen carrier, hemoglobin vesicles, can be safely used under conditions of hepatic impairment, Toxicology and Applied Pharmacology, 248巻, 3号, pp. 234-241, 20101101
  196. Evaluation of carboxymethyl-β-cyclodextrin with acid function: Improvement of chemical stability, oral bioavailability and bitter taste of famotidine, International Journal of Pharmaceutics, 397巻, 1-2号, pp. 1-8, 20100901
  197. Evaluation for antioxidant and renoprotective activity of olmesartan using nephrectomy rats, Biological and Pharmaceutical Bulletin, 32巻, 12号, pp. 2041-2045, 20091201
  198. Hemoglobin vesicles, polyethylene glycol (PEG)ylated liposomes developed as a red blood cell substitute, do not induce the accelerated blood clearance phenomenon in mice, Drug Metabolism and Disposition, 37巻, 11号, pp. 2197-2203, 20091101
  199. Pharmacokinetic study of enclosed hemoglobin and outer lipid component after the administration of hemoglobin vesicles as an artificial oxygen carrier, Drug Metabolism and Disposition, 37巻, 7号, pp. 1456-1463, 20090701
  200. Pharmacokinetics of single and repeated injection of hemoglobin-vesicles in hemorrhagic shock rat model, Journal of Controlled Release, 136巻, 3号, pp. 232-239, 20090619
  201. An oral adsorbent, AST-120 protects against the progression of oxidative stress by reducing the accumulation of indoxyl sulfate in the systemic circulation in renal failure, Pharmaceutical Research, 24巻, 7号, pp. 1283-1289, 20070701

著書等出版物

  1. Nanobiotherapeutic Based Blood Substitutes, Carbon monoxide-bound Hemoglobin-vesicles: Current facts and potential medical applications, World Scientific Publishing Co. Ltd., 2021年, Taguchi K, Matsumoto K, Sakai H, Maruyama T, Otagiri M
  2. DDS先端技術の製剤への応用開発, リポソーム製剤の骨髄へのDDS応用, 技術情報協会, 2017年, 宗慶太郎、田口和明
  3. Human Serum Albumin (HSA): Functional Structure, Synthesis and Therapeutic Uses, Pharmacokinetically modified human serum albumin based therapeutic design and development, Nova Science Publishers, Inc., 2015年, Taguchi K, Chuang VTG, Yamasaki K, Otagiri M
  4. HUMAN SERUM ALBUMIN, Albumin dialysis, Sojo University publisher, 2013年, Taguchi K, Chuang VTG, Otagiri M
  5. Acute Phase Proteins, Molecular aspects of human alpha-1 acid glycoprotein — Structure and function, Intech Open Ltd., 2013年, Taguchi K, Nishi K, Chuang VTG, Maruyama T, Otagiri M

招待講演、口頭・ポスター発表等

  1. ヘム鉄原子価に着目したヘモグロビン製剤の創剤研究, 田口和明, 日本薬剤学会第40回年会, 2025年, 招待, 日本語
  2. 良質な薬物治療を目指したアカデミア創薬・育薬研究, 田口和明, 日本薬学会第144年会, 2024年, 招待, 日本語
  3. ヘモグロビン小胞体投与が薬物動態関連タンパク質に与える影響, 田口和明、酒井宏水、松元一明、小田切優樹, 第30回日本血液代替物学会, 2023年, 招待, 日本語
  4. セルフメディケーション税制に対する理解度と意識の実態調査, 田口和明, 医療経済研究会, 2023年, 招待, 日本語
  5. 一酸化炭素結合型ヘモグロビン小胞体の薬剤誘発性臓器傷害に対する抑制効果, 田口和明、酒井宏水、小田切優樹、松元一明, 第29回日本血液代替物学会, 2022年, 招待, 日本語
  6. 長期備蓄を目指した凍結乾燥粉末化メトヘモグロビン-アルブミンクラスター, 田口和明、鈴木悠斗、岡本航、小松晃之、松元一明, 第29回日本血液代替物学会, 2022年, 招待, 日本語
  7. Research on pharmacokinetic analysis and safety evaluation for clinical development of artificial blood, Taguchi K, 日本薬物動態学会第36回年会, 2021年, 招待, 日本語
  8. ヘモグロビンを用いた一酸化炭素製剤の開発, 田口和明、小田切優樹、松元一明, 第28回日本血液代替物学会, 2021年, 招待, 日本語
  9. 赤血球バイオミメティックによる生理活性ガス送達戦略と難治性疾患治療への展開, 田口和明, 第37回日本DDS学会学術集会, 2021年, 招待, 日本語
  10. Medical application of hemoglobin-based artificial blood by delivering carbon monoxide, Taguchi K, Maruyama T, Matsumoto K, Sakai H, Otagiri M, 第85回日本循環器学会学術集会, 2021年, 招待, 日本語

受賞

  1. 2025年05月24日, 旭化成創剤研究奨励賞, 日本薬剤学会
  2. 2021年11月18日, 日本薬物動態学会奨励賞, 日本薬物動態学会
  3. 2021年06月30日, 日本DDS学会奨励賞 (臨床), 日本DDS学会
  4. 2020年03月25日, 日本薬学会奨励賞, 日本薬学会
  5. 2017年11月25日, 日本薬学会九州支部学術奨励賞, 日本薬学会
  6. 2011年03月25日, 熊本大学学長賞, 熊本大学

取得

  1. 特許権, 特許第6523842号, 横紋筋融解症治療剤